MDL-104

N/A

Report date: 2026/04/08 15:33:02

Base Information

Drug NameMDL-104
Drug Alias NameCRISPR-GNDM gene editing therapyCRISPR/dCas9 gene therapyMDL-104
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsTauopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesModalis Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesModalis Therapeutics Corp
Inactive CompaniesN/A
Active IndicationsTauopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A